SecBot SecBot
SECBOTREPLAY Home › Report › PRAX

PRAX · Praxis Precision Medicines announced that the FDA has accepted its New…

Praxis Precision Medicines, Inc. · PRESS-RELEASE filed Apr 14, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 14, 2026 at 07:30 ET

Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for ulixacaltamide HCl to treat essential tremor, with a PDUFA target action date of January 29, 2027. The FDA does not plan to hold an advisory committee meeting, accelerating the review timeline.

  • FDA accepted NDA for ulixacaltamide HCl for essential tremor with PDUFA date of January 29, 2027
  • No advisory committee meeting planned, indicating streamlined review process
  • NDA supported by positive Phase 3 Essential3 trial results showing statistically and clinically significant efficacy
  • Ulixacaltamide received Breakthrough Therapy Designation in December 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access